U.S. Issues Cuba Health Alert as Illnesses Rise 
AMD Hits $1 Trillion as BofA Raises Price Target to $720 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
BlackBerry Shares Rise as Q2 Earnings, Revenue Beat Estimates 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
Select Water Solutions Shares Surge on $700 Million Pilot Water Deal 
SMBC Eyes 20% VPBank Stake in Vietnam Expansion 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
FDA Approves Mirum’s Atebrioz for Rare Bone Disorder FOP 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Oura IPO Draws Strong Demand Ahead of $2.2 Billion Offering 
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Costco Revenue Beats Estimates as Inflation Drives Bulk Shopping 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Add as a preferred source on Google
Novo Nordisk A/S has finalized a groundbreaking deal to address the rising demand for its weight-loss drug, Wegovy, and diabetes treatment, Ozempic. In a significant move, Novo's largest shareholder has acquired Catalent Inc., one of the world's leading drug-manufacturing companies, for a staggering $16.5 billion, including debt.
As per Reuters, this three-way arrangement will see the Danish pharmaceutical company pay $11 billion to obtain three of Catalent's manufacturing facilities, fortifying its supply chain and overcoming recent shortages of Wegovy and Ozempic.
Fierce Competition and the Emergence of Zepbound
Novo Nordisk races to enhance its supply chain but faces fierce competition from Eli Lilly & Co. Lilly's obesity shot, Zepbound, was recently approved and is expected to become the highest-selling drug in history.
Yahoo pointed out that patient trials have demonstrated greater weight loss results with Lilly's drug compared to anything Novo has developed thus far. With this in mind, Novo's strategic acquisition of Catalent aims to solidify its market position and fend off the intensifying rivalry.
Novo Nordisk's purchase of Catalent has garnered support from Elliott Investment Management, an activist investor with a stake in the US company. The agreement values Catalent at $63.50 per share in cash, reflecting a 17% premium to its Friday closing price. However, Catalent faced manufacturing issues in September 2021, affecting its production of COVID-19 vaccines for Moderna Inc. and one of Regeneron Inc.'s top-selling drugs.
Novo Nordisk's Strategic Move to Meet Surging Demand Boosts its Market Value
Shares of Novo Nordisk have been surging alongside the increasing demand for its obesity and diabetes drugs, reaching a record high. With a market value exceeding $520 billion, Novo is now Europe's largest publicly traded company. Meanwhile, Catalent's stock rose by up to 10% in New York as news of the deal emerged.
This monumental $16.5 billion agreement between Novo Nordisk and Catalent marks the largest deal ever for companies and their controlling shareholder, Novo Holdings A/S. Novo Holdings currently controls 77% of the voting rights in the Danish drugmaker, further solidifying its influence and position in the pharmaceutical industry.
Photo: Novo Nordisk Newsroom
